Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Assets: 2013-2025

Historic Assets for Fortress Biotech (FBIO) over the last 13 years, with Sep 2025 value amounting to $181.4 million.

  • Fortress Biotech's Assets rose 42.74% to $181.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $181.4 million, marking a year-over-year increase of 42.74%. This contributed to the annual value of $144.2 million for FY2024, which is 13.91% down from last year.
  • Fortress Biotech's Assets amounted to $181.4 million in Q3 2025, which was up 13.45% from $159.9 million recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Assets registered a high of $418.2 million during Q2 2021, and its lowest value of $127.1 million during Q3 2024.
  • For the 3-year period, Fortress Biotech's Assets averaged around $169.4 million, with its median value being $164.6 million (2024).
  • In the last 5 years, Fortress Biotech's Assets soared by 70.94% in 2021 and then tumbled by 53.47% in 2023.
  • Over the past 5 years, Fortress Biotech's Assets (Quarterly) stood at $396.5 million in 2021, then decreased by 25.78% to $294.3 million in 2022, then tumbled by 43.08% to $167.5 million in 2023, then declined by 13.91% to $144.2 million in 2024, then spiked by 42.74% to $181.4 million in 2025.
  • Its last three reported values are $181.4 million in Q3 2025, $159.9 million for Q2 2025, and $178.1 million during Q1 2025.